IP Library Granted Patent US 10,174,325
Granted Patent B2
US 10,174,325 · App. 15/693,361 · Granted Jan 8, 2019

Compositions and methods for inhibiting Factor D

Inventors: Carl Erickson (Corte Madera, CA); Christopher P. Rusconi (Durham, NC); Kevin G. McLure (Oakland, CA)
Assignee: Vitrisa Therapeutics, Inc.
C12N15/115A61K31/7105C12N2310/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,174,325
App. No.
15/693,361
Granted
Jan 8, 2019
Kind
B2
Abstract

The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.

Claims (8)

1. An aptamer that selectively blocks a catalytic cleft of complement Factor D (fD), wherein said aptamer comprises a nucleic acid sequence that does not comprise any one of SEQ ID NOs: 73-80.

2. The aptamer of claim 1 , wherein said aptamer inhibits a function associated with fD.

3. The aptamer of claim 1 , wherein said aptamer is an RNA aptamer or a modified RNA aptamer.

4. The aptamer of claim 1 , wherein said aptamer is a DNA aptamer or a modified DNA aptamer.

5. The aptamer of claim 1 , wherein said aptamer inhibits a function of fD with an IC 50 of about 50 nM or less as measured by an alternative complement-dependent hemolysis assay.

6. The aptamer of claim 1 , wherein said aptamer inhibits activity of fD as compared to a control when measured by a fD esterase activity assay.

7. The aptamer of claim 1 , wherein said aptamer inhibits activity of fD as measured by a hemolysis assay.

8. The aptamer of claim 1 , wherein said aptamer selectively binds to fD with a K d of less than about 50 nM.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2024
From: 396419 B.C. LTD.; CALW INVESTMENT CO. INC.
To: OAK BAY BIOSCIENCES INC.
Reel/Frame 066421/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2024
From: 396419 B.C. LTD.
To: CALW INVESTMENT CO. INC.
Reel/Frame 066421/0557 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2020
From: VITRISA THERAPEUTICS, INC.
To: 396419 B.C. LTD.
Reel/Frame 052929/0171 →
SECURITY INTEREST Recorded Apr 17, 2019
From: VITRISA THERAPEUTICS, INC.
To: SILICON VALLEY BANK
Reel/Frame 048907/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2018
From: ERICKSON, CARL; RUSCONI, CHRISTOPHER P.; MCLURE, KEVIN G.
To: VITRISA THERAPEUTICS, INC.
Reel/Frame 045356/0489 →
Continuity (4)
Continuation PCTUS2017014458 · Jan 20, 2017
Provisional Application 62297095 · Feb 18, 2016
Provisional Application 62281092 · Jan 20, 2016
Related Publication 20180051287A1 · Feb 22, 2018